Optimizing hemostasis with antifibrinolytics is becoming a common surgical practice. Large clinical studies have demonstrated efficacy and safety of tranexamic acid (TXA) in the trauma population to reduce blood loss and transfusions. Its use in patients without pre-existing coagulopathies is debated, as thromboembolic events are a concern. In this review, perioperative administration of TXA is examined in nontrauma surgical populations. Additionally, risk of thromboembolism, dosing regimens, and timing of dosing are assessed.
INTRODUCTION
First, stop the bleeding! As anesthesiologists on the front line of trauma and acutely bleeding surgical patients, we must continuously seek mechanisms to promote hemostasis. The problem is severely injured trauma patients in shock develop an acute coagulopathy manifested by reduced clot strength and hyperfibrinolysis. The Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage 2 (CRASH II) and Military Application of Tranexamic Acid in Trauma Emergency Resuscitation study (MATTERs) trials addressed this problem and provided evidence that antifibrinolytics such as tranexamic acid (TXA) reduce all-cause mortality in the trauma population [1, 2] . Intuitively, this makes sense. Bleeding to death in the first 48 h after trauma accounts for approximately 50% of all deaths [3] . By blocking clot breakdown, we promote hemostasis and reduce death due to bleeding. In recent years, however, the results of the CRASH II and MATTERs trials have been extrapolated to nontrauma surgery. The problem is surgical patients with normal hemostatic function preoperatively may excessively bleed due to the surgery itself, thus, requiring transfusion. It is well known that antifibrinolytics have been used for years in surgery wherein the risk of bleeding is severe. Cardiac surgery and liver transplantation have provided a wealth of data on antifibrinolytic use. However, the risk of concurrent coagulopathies is great in both of these populations [4, 5] . In this article, we will discuss regulation of the fibrinolytic pathway and how it is altered in trauma. Next, we will review and summarize the use of antifibrinolytics, specifically TXA, in recent literature. Finally, we will summarize recent antifibrinolytic use in nontrauma populations and conclude with recommendations.
REGULATION OF FIBRINOLYSIS
Fibrinolysis is the process of clot degradation that promotes fluidity, effectively recanalizing a vessel occluded by thrombus [6] . During normal coagulation, fibrinogen is converted to fibrin, which incorporates into bound platelets and forms a hemostatic clot at the point of vascular injury. After hemostasis is achieved, the clot is enzymatically broken down. This process requires the conversion of inactive single-chain plasminogen (PLG) to an active two-chain protease. Fibrinolysis is, therefore, initiated when PLG is converted to plasmin by tissue plasminogen activator (t-PA). Tissue t-PA is the principal PLG-activator in plasma and has a relatively weak affinity for PLG. However, in the presence of fibrin, t-PA's affinity for PLG is increased several fold [7] . Tissue t-PA is released due to venous occlusion, stress, physical activity, or vasoactive drugs such as epinephrine. Figure 1 graphically depicts fibrinolysis.
Whereas plasmin cannot circulate freely in plasma because of rapid inactivation by antiplasmin, PLG can. PLG incorporates into the evolving thrombus due to its high affinity for fibrin, mediated by lysine-binding domains [7] . During clot evolution, thrombin is shed into circulation wherein it binds thrombomodulin located on the endothelial surface. This complex activates protein C that in turn blocks inactivation of t-PA by inhibiting t-PA inhibitor [8 && ]. Locally synthesized t-PA binds PLG within the thrombus to form plasmin and begins enzymatic breakdown into fibrin degradation products. As fibrin is broken down, more lysine binding sites are exposed, binding more PLG, thus, enhancing plasmin formation. Lysine analogues such as TXA can bind these lysine cites and block plasmin formation.
To prevent widespread fibrinolysis, the system has several checks or inhibitors. First, t-PA binding is enhanced in the presence of fibrin, thus only binds locally to PLG within thrombus. Next, platelets and thrombin stimulate the release of t-PA inhibitor that slows plasmin formation. Antiplasmins circulating in the plasma also quickly inactivate any plasmin released from the thrombus.
COAGULOPATHY IN TRAUMA
In approximately one-third of all trauma patients, the degree of shock and hypoperfusion will be sufficient to induce an endogenous biological process resulting in coagulopathy [9] . It is important to realize that injury severity and resulting shock is an important instigator in trauma induced coagulopathy (TIC) and carries a 50% mortality when diagnosed [10] . Multiple mechanisms contribute to the hypocoagulable state after severe trauma ( Table 1 ). The discovery of TIC as an endogenous process that occurs outside of hemodilution, hypothermia, and acidemia spurred the development of new resuscitation strategies. Damage control or hemostatic resuscitation consists of limiting crystalloid administration, rapid rewarming, time-limited hypotension during hemorrhage, and emphasis on ratio based blood components to mimic whole blood administration [11 & ,12] . A central tenet of damage control resuscitation is to treat the altered
KEY POINTS
In severe trauma with shock, TXA is used to treat hyperfibrinolysis and is part of a damage control resuscitation strategy.
Large clinical trials have demonstrated reduction in blood transfusions without increased incidence of thromboembolic events in the trauma population when TXA is administered.
Ideal dosing regimens for trauma and nontrauma surgeries are still under investigation.
In nontrauma surgery, perioperative use of TXA is associated with improved surgical field views, reduced blood loss, and fewer blood transfusions.
TXA has not been shown to statistically increase thromboembolic events in the perioperative period. biology manifested during trauma. One important alteration appreciated in TIC is hyperfibrinolysis. For this reason, the CRASH II trial studied administration of TXA, an antifibrinolytic, and found that early administration of this drug decreased all-cause mortality after severe trauma [1] .
Protein C activation
Two prospective studies have shown conclusively that protein C is activated early after severe trauma and acts as a driver of TIC [13,14 && ]. After severe traumatic injury and in the presence of hypoperfusion, thrombin is released systemically into the circulation and binds with thrombomodulin and the endothelial protein C receptor. This complex then activates circulating protein C and results in a 'thrombin switch' wherein thrombin paradoxically becomes an initiator of anticoagulation [15, 16] . Activated protein C (APC) has multiple anticoagulant functions. First, by inhibiting factors V and VIII, thrombin generation is impaired, ultimately halting clot formation. Next, APC inhibits t-PA inhibitor resulting in increased fibrinolysis. Finally, APC exerts profound anti-inflammatory effects by modulating transcription factors essential to cellular signaling [8 && ]. High circulating levels of APC upon admission were found to be predictors of poor outcomes such as increased mortality, organ injury, increased blood transfusion requirements, and reduced ICU ventilator-free days [17] . 
Endothelial injury
Perhaps as important as activation of protein C, injury to the endothelium is an important factor in the development of acute traumatic coagulopathy. The endothelium is lined with an anticoagulant rich, negatively charged surface layer called the glycocalyx. This 1-micron thick layer contains approximately 1 liter of noncirculating heparin-like substances [20] . Additionally, the endothelium comprises Weibel-Palade bodies that contain concentrated levels of tissue t-PA and angiopoietin 2 (Ang-2). When damaged, endothelial components such as syndecan-1, soluble thrombomodulin, Ang2, and t-PA are released into the circulation resulting in autoheparinization and hyperfibrinolysis [21] . Ostrowski and Johansson [21] observed that about 5% of severely injured trauma patients demonstrate autoheparinization and increased fibrinolysis on thromboelastometry. Two independent studies have shown that high circulating levels of syndecan-1 or Ang-2, both markers of endothelial damage, are predictors of increased mortality [22, 23] . Table 3 lists studies demonstrating the importance of endothelial injury in trauma [21, 23, 24] .
Fibrinogen depletion
Fibrinogen is an acute phase reactant with limited stores in the human body. Thus, depletion is rapid after severe trauma due to hemorrhagic loss. Additionally, enhanced fibrinolysis due to inactivation of t-PA inhibitor caused by APC also results in depleted fibrinogen due to consumption. Two studies by Rourke et al. [25] and Kornblith et al. [26 & ], demonstrate the significance of fibrinogen depletion. First, using different thromboelastography assays, Kornblith et al. showed convincingly that fibrinogen contributes about 30% to total clot strength. In trauma, patients with lower functional fibrinogen had greater transfusion requirements and higher mortality [26 & ]. Rourke et al. [25] demonstrated that fibrinogen is rapidly depleted after 
Platelet dysfunction
Although not directly contributing to hyperfibrinolysis, platelet exhaustion during trauma and its ensuing effects on cellular activation are important in the pathogenesis of TIC. Hoffman's cell-based model of hemostasis provides an excellent description of the integral role platelets play in coagulation [29] . Acting as the principal site of thrombin formation and as a key signaler of cellular activation, the platelet is instrumental in normal coagulation. Several studies have demonstrated significant inactivation of platelets after trauma despite normal platelet levels [30] . 
USE OF TRANEXAMIC ACID IN TRAUMA PATIENTS
It is well understood that the cause of death in nearly half of all trauma patients is life-threatening hemorrhage. Nearly all trauma patients suffer some form of coagulopathy [33] . TIC, which begins as early as at the time of injury [34] , is present in up to 40% of patients following major traumatic injury [3] . Early recognition and treatment of TIC may improve outcome in trauma resuscitation [35] . Historically, plasmabased testing (activated partial thromboplastin time, prothrombin time, international normalized ratio) has been used to monitor coagulation. Plasmabased testing is used extensively to monitor patients receiving anticoagulation but has not been validated in monitoring the hemorrhaging trauma patient [36, 37] . Viscoelastic monitoring [thromboelastograph, rapid thromboelastograph, rotational thromboelastometry, SONOCLOT (Sienco, Inc., Boulder, Colorado, USA)], cell-based testing, shows promise in diagnosing trauma-related coagulopathy and fibrinolysis [38] [39] [40] . Viscoelastic testing is still more common in European centers, but is gaining acceptance in American ones. Coagulopathy, requiring transfusion, remains a significant entity in critically ill bleeding patients. Transfusion of red blood cells and blood components are accompanied by the risks of allergic and hemolytic reactions. In addition, blood group mismatch, transfusion-related acute lung injury, transfusion-associated circulatory overload, bacterial transmission, and errors such as the mismatching of blood groups add to the risk of transfusion [41 && ]. The pathophysiology of traumatic coagulopathy is very different from postoperative bleeding; however, there exist similarities between the two such as defects in thrombin generation, plasmin generation, activation of the inflammatory response, as well as an imbalance between fibrin generation and breakdown [42] . The use of antifibrinolytics is encouraging and has been shown to reduce transfusion needs and bleeding, and temper hyperfibrinolysis, although more large prospective randomized trials are needed.
CRASH II trial
The CRASH II trial is the largest multinational randomized placebo controlled trial of the effects of the early administration of TXA on death (28-day mortality), thromboembolic events, and blood use in adult trauma patients. Thromboembolic events were defined as myocardial infarction, stroke, and pulmonary embolism. This randomized controlled trial was carried out in 274 hospitals in 40 countries and enrolled 20 211 adult trauma patients. Patients were randomized within 8 h of injury to either the TXA group (1 g loading dose over 10 min followed by an infusion of 1 g over 8 h) or a matching placebo [43] . Eligibility were those adult trauma patients with SBP lower than 90 mmHg or heart rate more than 110 beats per minute (defined as significant hemorrhage) and within 8 h of injury. Ten thousand and ninety-six patients were allocated to the TXA group and 10 115 patients were allocated to the placebo group. Nineteen thousand nine hundred and forty-four patients (99.1%) were known to have completed the loading dose and 18 965 (94.2%) the 8 h maintenance dose. Three thousand and seventy-six (15.3%) patients died, of those 1086 (35.3%) died on the day of randomization. There were 1063 deaths from bleeding of which 637 (59.9%) were on the day of randomization. All-cause mortality at 4 weeks was significantly reduced with relative risk (RR) of death for those treated with TXA of 0.91 [95% confidence interval (CI) 0.85-0.97, P ¼ 0.0035] [44] . The risk of death because of bleeding was also significantly reduced [TXA 489 (4.9%) vs. placebo 574 (5.7%)] RR 0.85 (95% CI 0.76-0.96, P ¼ 0.0077).
There was no statistically significant difference in the incidence of thromboembolic events including pulmonary embolism (PE), deep venous thrombosis (DVT), stroke or myocardial infarction, multiorgan failure, and head injury between the two groups. Head injury was the leading cause of death within both the TXA group and the placebo group (6.0% vs. 6.2%) RR 0.97 (95% CI 0.87-1.08, P ¼ 0.60). There was also no statistical difference for blood products transfused. The authors concluded that TXA safely reduced the risk of death from bleeding in the hemorrhaging trauma patient. In their opinion, TXA should be considered for administration in bleeding trauma patients.
There were significant limitations to the CRASH II trial such as a lack of massive transfusion protocol, the lack of information regarding additional blood product use, the approach to randomization and the lack of data regarding laboratory data and the extent of acute traumatic coagulopathy [44] .
CRASH II exploratory analysis: early TXA administration
This exploratory analysis of the CRASH II trial was carried out in order to determine the effects of TXA administration on death due to bleeding according to the time to treatment, type of injury (penetrating only, blunt, blunt and penetrating), Glasgow coma score (GCS), and SBP as an indication of severity of hemorrhage. There was convincing evidence that the rate of death because of hemorrhage varied according to the time from injury until treatment. Early treatment with TXA reduced the risk of death by bleeding if given within an hour of injury (Table 6 ) [1] . There was no significant increase in the risk of death from all other nonbleeding causes combined. The authors noted that caution should be taken when administering TXA to patients greater than 3 h out from time of injury. These may be two different patient populations. Those further out from injury (>3 h) may be more acidotic, hypothermic, and in a more prothrombotic phase of their traumatic injury [45, 46] .
MATTERs study
The MATTERs was designed to study the efficacy of TXA administration on mortality, total blood product use, and complications due to thromboembolic events in combat-related injuries. It is a retrospective observational study comparing TXA administration to no TXA in patients receiving at least one 23 .9%, P ¼ 0.03). This benefit was greater in the group receiving massive transfusion (14.4 vs. 28.1%, P ¼ 0.004). In this group, an independent association with survival as well as less coagulopathy was noted (odds ratio ¼ 7.228; 95% CI 3.016-17.322, P ¼ 0.003). Thirty-day survival was higher in the TXA group (P ¼ 0.004) in both the overall cohort as well as the group receiving massive transfusion. In the overall cohort, hypotension, a GCS 8 or less, and the presence of coagulopathy were associated with a higher mortality. In the massive transfusion group, a GCS of 8 or less and an injury severity score of at least 15 was associated with mortality but TXA use demonstrated an independent survival benefit. No clinical parameters had an association with DVT or PE in either cohort in a separate analysis. The authors concluded that TXA use, with component-based resuscitation, results in the improvement of coagulopathy and survival post combat injury. This result was more significant in those requiring a massive transfusion [2] .
MATTERs II study
This retrospective observational study of 1332 patients was designed to determine the association of cryoprecipitate and survival after combat injury. A secondary, but unforeseen, observation of the MATTERs study demonstrated an increase in volume of cryoprecipitate given to the cohort who received TXA. The study population consisted of four cohorts: casualties that received TXA but not cryoprecipitate, casualties that received cryoprecipitate but not TXA, casualties that received both cryoprecipitate and TXA, and casualties that received neither. The no TXA-no cryoprecipitate cohort demonstrated the highest mortality (23.6%) and the TXA-cryoprecipitate cohort had the lowest mortality (11.6%), (P ¼ 0.001). The effect of TXA was examined in order to determine if there was an interaction with cryoprecipitate. In a Synergy model, there was found to be no interaction between TXA and cryoprecipitate (P ¼ 0.21). The independent additive effect of TXA and cryoprecipitate in combination was found to have an odds ratio of 0.34 (95% CI 0.20-0.58) (P < 0.001). There appears to exist an additive effect between TXA and cryoprecipitate that is beneficial in terms of a survivor benefit when given to severely injured combat casualties requiring transfusion [47 && ].
USE OF TRANEXAMIC ACID IN NONTRAUMA PATIENTS
A very thorough review of the use of TXA in anesthetic practice was written in the British Journal of Patients also received Amicar as a comparator as well as placebo. Overall, those treated with TXA who required blood transfusions were decreased by 35% than those treated with Amicar and placebo. A dose-independent effect of TXA was also observed. They found blood loss was significantly decreased as well as transfusion requirement in the TXA treated group.
Oremus et al. [60] RCT, 2014 98 patients underwent TKA or THA. Patients randomized to TXA (1 g followed by 1 g 3 h later) or saline placebo. Proportion of patients receiving autologous blood reinfusion was lower in the TXA group than placebo, absolute difference of À75.5%. No differences in homologous transfusions and hematologic variables between groups. Authors conclude that with a blood salvage protocol and the addition of TXA, a postoperative blood salvage system is unnecessary.
Dahuja et al. [61] Prospective cohort, 2014 60 patients with primary osteoarthritis of both knees undergoing staged bilateral TKA at an interval of 3 weeks that had previously received TXA for the first procedure. Used as own controls. TXA 15 mg/kg given before tourniquet and then every 8 h for 2 days. Total postoperative drain output lower in the TXA group. Hematocrit and platelet count were similar. No thromboembolic events in both groups. TXA treated patients showed no bleeding tendency and increased fibrinogen levels.
THA, total hip arthroplasty; TKA, total knee arthroplasty. Anaesthesia in 2013 [41 && ]. This review examined the use of antifibrinolytics in multiple types of surgical populations. In summary, TXA use was associated with reduced allogenic blood transfusion without increased thromboembolic events. Benefits were seen in neurosurgical, obstetric, orthopedic, liver, and cardiac surgery. Limiting the dose of TXA due to its seizure-inducing properties was suggested.
The use of TXA in cardiac surgery (Table 7 ) continues to gain popularity since the removal of Aprotinin from the market but remains more costly than e-aminocaproic acid [48] [49] [50] [51] [52] [53] [54] .
The population pharmacokinetics of TXA in adults has been investigated with recommendations on dosing. The safety of antifibrinolytics in children requires further investigation. The question of increased thromboembolic events remains an important concern requiring more adequately powered randomized control trials (RCTs) [55] .
TXA in orthopedic surgery (Table 8 ) has shown great promise in reducing allogenic blood transfusions and is becoming integral to blood management strategies [56] [57] [58] [59] [60] [61] . Recent retrospective studies have not shown evidence of increased thromboembolic events. Larger RCTs are still needed to determine the ideal dosing and timing of TXA administration in this population. Likewise, head and neck surgery and obstetrics have found benefit in perioperative TXA administration (Table 9  [ [62] [63] [64] [65] [66] ). Recent studies support TXA use to reduce blood loss, whereas larger powered studies are needed to ascertain thromboembolic event risk.
Absolute and relative contraindications to TXA administration are listed in Table 10 .
CONCLUSION
TXA has gained much popularity in surgery because of its promotion of hemostasis. Although cardiac surgery, liver transplantation, and trauma have traditionally been the areas of antifibrinolytic use, other surgical venues are now exploring TXA benefits. The concern over using antifibrinolytics routinely to reduce intraoperative blood loss in patients without known coagulopathies is valid. Several studies have now shown reduced blood RCT, 2014 49 patients requiring a LeFort I osteotomy. Evaluated the efficacy of hypotensive anesthesia in combination with TXA on intraoperative blood loss. The TXA group received 10 mg/kg in a bolus preoperatively. Placebo group received saline 5 ml. The TXA group showed a statically significant reduction in blood loss (45%). Authors conclude a lower need for postoperative transfusion and a better operative field.
Robb [63] Review article, 2014
The use of TXA in ENT surgery needs further controlled randomized trials. Two recent pilot studies looked at primary hemorrhage in children and secondary hemorrhage in adults post tonsillectomy suggesting further RCTs needed.
Dakir et al. [64] Randomized pilot, 2014 12 patients 20-40 years of age with multiple facial fractures. 6 received TXA 10 mg/kg before induction of anesthesia and 6 were allocated to the saline placebo group. The TXA group had a significantly reduced blood loss compared with placebo (489.17 AE 106.7 vs. 900.83 AE 113.7 ml.) None of the TXA group required a blood transfusion.
Heesen et al. [65] Meta-analysis,2014 Seven trials with low risk of bias comparing TXA to placebo in 1760 parturients. Blood loss was significantly lower in the TXA group as was the needs for blood transfusion (RR 0.34, P ¼ 0.0001). Uterotonics were needed more in the placebo group and more gastrointestinal adverse events were noted in the TXA group. Thromboembolic events were not significant in either group.
Perel et al. [66] Cochrane review, 2013 Five trials were identified (372 people) and 3 trials (260 people) contributed to the data. The effect of TXA on mortality was uncertain (RR 1.01; 95% CI 0.14-7.3). TXA reduced the probability of blood transfusion. The effects on DVT (RR 2.29; 95% CI 0.68-7.66) and stroke (RR 2.79; 95% CI 0.12-67.10) were uncertain. CI, confidence interval; RR, relative risk. transfusion and reduced intraoperative blood loss when administering TXA. Importantly, there does not appear to be a morbidity burden from increased thromboembolic events. More RCTs need to be conducted to determine appropriate dosing regimens for different surgical populations. In addition, timing of administration appears to be critical for optimal effect of hemostasis without increasing risk of thromboembolism. At this time, it appears that using TXA in nontrauma surgery to promote hemostasis reduces blood loss and does not increase thromboembolic phenomenon.
